John Weinstein, M.D. Ph.D. Appointed to ACLARA Scientific Advisory Board
11 Dezember 2003 - 2:00PM
PR Newswire (US)
John Weinstein, M.D. Ph.D. Appointed to ACLARA Scientific Advisory
Board Prominent NCI Cancer Expert Added to Advisory Board MOUNTAIN
VIEW, Calif., Dec. 11 /PRNewswire-FirstCall/ -- ACLARA BioSciences
announced that John N. Weinstein, M.D. Ph.D. of Bethesda, MD has
been appointed to its Scientific Advisory Board. Dr. Weinstein's
research focus is the molecular pharmacology of cancer cells
utilizing techniques such as gene expression profiling and
bioinformatics, and the identification and characterization of new
agents for the treatment of cancer. ACLARA's advisory board now
comprises five internationally-renowned scientists and physicians
with interests covering both basic research and clinical treatment
of a range of different cancers and immune system disorders. "We
are particularly pleased to have a prominent scientist such as Dr.
Weinstein join the advisory board as he is actively involved in
fundamental cancer research. The application of eTag(TM) assays to
the clinical evaluation of potential cancer drugs is emerging as a
very exciting opportunity, and we look forward to Dr. Weinstein's
advice and counsel as we commercialize this application," commented
Thomas Klopack, ACLARA chief executive officer. ACLARA's eTag
assays enable pharmaceutical researchers and physicians involved in
clinical trials to test patient samples and identify subtle but
important protein differences among patients. This information
facilitates the identification of those patients most likely to
respond to a particular pharmaceutical compound or treatment
regimen, based on the disease mechanisms detected at the molecular
and cellular level. About ACLARA ACLARA BioSciences, Inc. is
commercializing its proprietary eTag Assay System for drug
discovery research and to support preclinical and clinical
development of specific targeted therapies. The eTag Assay System
is a high performance, high throughput system for the simultaneous
measurement of 10's to 100's of genes, proteins, and cell-based
antigens across thousands of samples. The eTag platform makes it
possible for researchers to measure multiple aspects of a complex
biological system, enabling the study of gene expression, protein
expression, cell signaling and pathway activation, protein-protein
interaction, post-translational modifications and cell receptor
binding -- all in the same sample and with the same platform. The
system uses ACLARA's proprietary eTag reporters to multiplex the
analysis of genes and/or proteins. Specific molecular binding
events result in the release of electrophoretically distinct eTag
reporters, which are then resolved by standard capillary
electrophoresis to provide precise, sensitive quantitation of
multiple analytes -- directly from cell lysates of cultured or
primary cells, as well as fresh and fixed tissue samples. More
information on ACLARA can be obtained on the Company's web site at
http://www.aclara.com/. Forward Looking Statement All statements in
this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of
1934 as amended. Such forward-looking statements are subject to
factors that could cause actual results to differ materially for
ACLARA from those projected. Those factors include risks and
uncertainties relating to the performance of the Company's
products, product development, development and commercialization
efforts, successful establishment of and performance under
collaborative and commercial agreements, adoption of its
technologies by pharmaceutical and biotechnology companies, the
validity and enforceability of patents, the possible infringement
of the intellectual property of others, technological approaches of
ACLARA and its competitors, and other risk factors identified in
the Company's Form 10-K for the year ended December 31, 2002 and
Form 10-Q for the quarter ended September 30, 2003 as filed with
the Securities and Exchange Commission. Trademarks ACLARA
BioSciences is a registered trademark, and eTag and the ACLARA logo
are trademarks of ACLARA BioSciences, Inc. DATASOURCE: ACLARA
BioSciences, Inc. CONTACT: Alfred Merriweather, VP, Finance and CFO
of ACLARA, +1-650-210-1200, or Web site: http://www.aclara.com/
Copyright
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Aclara Biosciences, (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Aclara Biosciences, (MM) News-Artikel